Biotech IPO freeze continues as second quarter is slowest in more than a decade
Bausch + Lomb’s $ 630 million IPO was the biggest one in the second quarter of this year. It was also an outlier. The steep drop off in IPO activity continued in the most recent quarter, which saw the number of completed new stock offerings dip to levels last seen in the Great Recession of … Read more